Assessing Blueprint Medicines: Insights From 16 Financial Analysts


In the preceding three months, 16 analysts have released ratings for Blueprint Medicines BPMC, presenting a wide array of perspectives from bullish to bearish.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 7 5 3 0 1
Last 30D 0 1 0 0 0
1M Ago 0 1 0 0 0
2M Ago 7 3 3 0 1
3M Ago 0 0 0 0 0

The 12-month price targets, analyzed by analysts, offer insights with an average target of $115.5, a high estimate of $168.00, and a low estimate of $75.00. Marking an increase of 19.69%, the current average surpasses the previous average price target of $96.50.

Analyzing Analyst Ratings: A Detailed Breakdown

A comprehensive examination of how financial experts perceive Blueprint Medicines is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Reni Benjamin JMP Securities Maintains Market Outperform $125.00 $125.00
Sudan Loganathan Stephens & Co. Announces Overweight $140.00 -
Andrew Berens Leerink Partners Raises Market Perform $97.00 $50.00
Terence Flynn Goldman Sachs Raises Buy $168.00 $121.00
David Lebowitz Citigroup Raises Sell $76.00 $65.00
Andrew Fein HC Wainwright & Co. Raises Buy $135.00 $125.00
Reni Benjamin JMP Securities Raises Market Outperform $125.00 $114.00
Peter Lawson Barclays Raises Equal-Weight $75.00 $70.00
Christopher Raymond Piper Sandler Raises Neutral $104.00 $78.00
Ami Fadia Needham Raises Buy $130.00 $97.00
Ami Fadia Needham Maintains Buy $97.00 -
Bradley Canino Stifel Raises Buy $130.00 $120.00
David Nierengarten Wedbush Maintains Outperform $110.00 -
Andrew Fein HC Wainwright & Co. Maintains Buy $125.00 -
Ami Fadia Needham Maintains Buy $97.00 -
Reni Benjamin JMP Securities Maintains Market Outperform $114.00 -

Key Insights:

  • Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Blueprint Medicines. This offers insight into analysts' perspectives on the current state of the company.
  • Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Blueprint Medicines compared to the broader market.
  • Price Targets: Gaining insights, analysts provide estimates for the future value of Blueprint Medicines's stock. This comparison reveals trends in analysts' expectations over time.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Blueprint Medicines's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on Blueprint Medicines analyst ratings.

All You Need to Know About Blueprint Medicines

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.

Blueprint Medicines: Delving into Financials

Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.

Revenue Growth: Blueprint Medicines displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 51.87%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.

Net Margin: Blueprint Medicines's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 92.74% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Blueprint Medicines's ROE excels beyond industry benchmarks, reaching 40.4%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Blueprint Medicines's ROA stands out, surpassing industry averages. With an impressive ROA of 8.54%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: Blueprint Medicines's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.06.

Analyst Ratings: What Are They?

Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Price Target
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!